PDE9A Inhibitors Elevate Treg Levels for IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) are ineffective for over 35% of patients and often come with adverse reactions, highlighting the need for alternative therapeutic approaches.
Innovation Solution
The use of PDE9A inhibitors, such as BAY 73-6691, PF-04447943, PF-04449613, and PF-418366, to increase the levels of Regulatory T cells (Treg) and reduce inflammatory responses in the intestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs (5-aminosalicylic acid, adrenocortical hormone, immunosuppressive agents, biological agents) are used to treat IBD, then treatment coverage is provided for many patients, but more than 35% of patients remain untreated and 29-37% experience adverse reactions
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (PDE9A enzyme) underlying IBD pathogenesis, isolating this particular pathway from the complex disease process. By focusing on PDE9A inhibition rather than broad immunosuppression, the treatment achieves specificity that reduces off-target adverse reactions while maintaining effectiveness for previously untreated patients
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific immunosuppression to specific PDE9A enzyme inhibition. This parameter change transforms the treatment mechanism from broad immune system suppression to targeted cyclic nucleotide metabolism modulation, thereby reducing adverse reactions while improving treatment effectiveness for the 35% of patients who previously received no effective therapy
2Reliability
If PDE9A inhibitors are used to increase Treg levels and reduce inflammatory responses, then treatment effectiveness for IBD is improved, but the mechanism involves complex intracellular signaling pathways (cAMP, cGMP, PKA/PKG activation)
Solution Approach 1:
The patent uses PDE9A inhibition as an intermediary mechanism to indirectly regulate Treg levels and inflammatory responses. Rather than directly manipulating complex immune cell populations or cytokine networks, the treatment acts on the PDE9A enzyme as a mediator, which then triggers downstream effects on cAMP/cGMP levels, PKA/PKG activation, and ultimately Treg function. This intermediary approach simplifies the therapeutic target while achieving complex immunomodulatory effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PDE9A inhibitors effectively enhance Treg levels and reduce pro-inflammatory cytokines, improving mucosal mucus secretion, SOD activity, and reducing oxidative stress and immune cell differentiation, thereby controlling the progression of IBD.
Implementation Method 1
Phosphodiesterases (PDEs) are enzymes that degrade intracellular cyclic nucleotides, such as cAMP and cGMP, and PDE cleaves 3'-phosphate by hydrolysis. The bond inactivates the cyclic nucleotide to form the corresponding inactive monophosphate product. Selective inhibition of PDEs by phosphodiesterase inhibitors (PDEI) causes intracellular cAMP and elevated levels of GMP to lead to enhanced protein kinase A/G (PKA/PKG) activation and protein phosphorylation
Implementation Method 2
PDE9A inhibitors effectively enhance Treg levels and reduce pro-inflammatory cytokines, improving mucosal mucus secretion, SOD activity, and reducing oxidative stress and immune cell differentiation
Data Source
AI summary
The present invention relates to the field of medicine, and related to an application of a PDE9A inhibitor in the preparation of products having an elevated Treg content, drugs for preventing and treating inflammatory bowel disease, and health care products. The PDE9A inhibitor may improve the secretion of mucosal mucus in an intestinal tract suffering from inflammatory bowel disease, reduce the secretion of TNF-α, IL-6, IL-17 and IL-12/IL-23 pro-inflammatory factors, inhibit DC cell differentiation and migration, increase the ratio Foxp3+Treg cells, promote the movement of CD4+CD25+ Treg cells from the spleen and mesenteric lymph nodes to the colon, thereby inhibiting an intestinal inflammatory response and controlling the occurrence and development of the disease. When PDE9A inhibitor is applied to a drug for preventing and treating inflammatory bowel disease, inflammatory bowel disease may be effectively prevented, alleviated and treated, while healthcare products containing said inhibitor as an active ingredient may regulate the intestinal tract of patients suffering from inflammatory bowel disease and control the occurrence and development of inflammatory bowel disease.